Literature DB >> 18570958

Primary and salvage total laryngectomy.

Nishant Agrawal1, David Goldenberg.   

Abstract

Treatment of laryngeal cancer has evolved, and newer methods of laryngeal conservation, both surgical and nonsurgical, are the primary treatment of choice. Nevertheless, total laryngectomy is not extinct and still plays an important role in primary therapy for advanced stage laryngeal cancers and as salvage therapy for failures of organ preservation strategies.

Entities:  

Mesh:

Year:  2008        PMID: 18570958     DOI: 10.1016/j.otc.2008.02.001

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  5 in total

1.  [Laryngectomy-still state of the art?]

Authors:  J M Vahl; P J Schuler; J Greve; S Laban; A Knopf; T K Hoffmann
Journal:  HNO       Date:  2019-12       Impact factor: 1.284

Review 2.  Current trends in initial management of laryngeal cancer: the declining use of open surgery.

Authors:  Carl E Silver; Jonathan J Beitler; Ashok R Shaha; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-07-14       Impact factor: 2.503

Review 3.  Transoral laser microsurgery for laryngeal cancer: a primer and review of laser dosimetry.

Authors:  Marc Rubinstein; William B Armstrong
Journal:  Lasers Med Sci       Date:  2010-09-11       Impact factor: 3.161

4.  The usefulness of a pectoralis major myocutaneous flap in preventing salivary fistulae after salvage total laryngectomy.

Authors:  Alexandre Andrade Sousa; Sebastião Maurício de Oliveira Castro; José Maria Porcaro-Salles; João Marcos Arantes Soares; Gustavo Meyer de Moraes; Jomar Rezende Carvalho; Guilherme Souza Silva
Journal:  Braz J Otorhinolaryngol       Date:  2012 Jul-Aug

5.  Transoral ultrasonic total laryngectomy (TOUSS-TL): description of a new endoscopic approach and report of two cases.

Authors:  Mario M Fernández-Fernández; Lourdes Montes-Jovellar González; Carlos Ramírez Calvo; Pablo Parente Arias; Francisco Clascá Cabré; Primitivo Ortega Del Álamo
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-01       Impact factor: 2.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.